Literature DB >> 9466540

CD8 cell noncytotoxic antiviral activity in human immunodeficiency virus-infected and -uninfected children.

J A Levy1, F Hsueh, D J Blackbourn, D Wara, P S Weintrub.   

Abstract

CD8 cells from human immunodeficiency virus (HIV)-infected adults and children can show cytotoxic as well as noncytotoxic activity against viral replication. The noncytotoxic anti-HIV response, measured by suppression of acute viral infection of CD4 cells, has also been observed in uninfected adults who have a history of exposure to HIV. This CD8 cell antiviral activity was found to be detectable as well in approximately 50% of uninfected children born of infected mothers. The findings could reflect a protective response of the children to HIV after being exposed to the virus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466540     DOI: 10.1086/517378

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

Review 1.  The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.

Authors:  C Farquhar; G John-Stewart
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

Review 2.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

3.  Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level.

Authors:  A L Erickson; C B Willberg; V McMahan; A Liu; S P Buchbinder; L A Grohskopf; R M Grant; D F Nixon
Journal:  Clin Vaccine Immunol       Date:  2008-09-24

4.  CD8(+)-Cell antiviral factor activity is not restricted to human immunodeficiency virus (HIV)-specific T cells and can block HIV replication after initiation of reverse transcription.

Authors:  S Le Borgne; M Février; C Callebaut; S P Lee; Y Rivière
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  In vivo effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1-seropositive mothers.

Authors:  Diana B Schramm; Louise Kuhn; Glenda E Gray; Caroline T Tiemessen
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

Review 6.  A Meta-analysis Assessing Diarrhea and Pneumonia in HIV-Exposed Uninfected Compared With HIV-Unexposed Uninfected Infants and Children.

Authors:  Alana T Brennan; Rachael Bonawitz; Christopher J Gill; Donald M Thea; Mary Kleinman; Lawrence Long; Caitryn McCallum; Matthew P Fox
Journal:  J Acquir Immune Defic Syndr       Date:  2019-09-01       Impact factor: 3.731

7.  Changes in soluble factor-mediated CD8+ cell-derived antiviral activity in cynomolgus macaques infected with simian immunodeficiency virus SIVmac251: relationship to biological markers of progression.

Authors:  Vincent Dioszeghy; Kadija Benlhassan-Chahour; Benoit Delache; Nathalie Dereuddre-Bosquet; Celine Aubenque; Gabriel Gras; Roger Le Grand; Bruno Vaslin
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

8.  Natural suppression of human immunodeficiency virus type 1 replication is mediated by transitional memory CD8+ T cells.

Authors:  M Scott Killian; Carl Johnson; Fernando Teque; Sue Fujimura; Jay A Levy
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

Review 9.  Mucosal correlates of protection in HIV-1-exposed sero-negative persons.

Authors:  Ruizhong Shen; Phillip D Smith
Journal:  Am J Reprod Immunol       Date:  2014-01-16       Impact factor: 3.886

10.  Immunohistochemical evaluation of T cells in oral lesions from human immunodeficiency virus-positive persons with oropharyngeal candidiasis.

Authors:  Tammy A Myers; Janet E Leigh; Alfredo R Arribas; Shannon Hager; Rebecca Clark; Elizabeth Lilly; Paul L Fidel
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.